Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

24.25
-1.5900-6.15%
Volume:2.22M
Turnover:54.97M
Market Cap:300.87M
PE:-2.55
High:25.74
Open:25.08
Low:24.19
Close:25.84
Loading ...

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

Benzinga
·
25 Jun

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

TIPRANKS
·
25 Jun

Nektar Therapeutics : H.c. Wainwright Raises Target Price to $120 From $6.5

THOMSON REUTERS
·
25 Jun

Nektar Shares Double to $19.8 After Eczema Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
24 Jun

BUZZ-U.S. STOCKS ON THE MOVE-US airlines, Snowflake, Supermicro

Reuters
·
24 Jun

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
24 Jun

Nektar jumps 130% to $21.90 after atopic dermatitis study success

TIPRANKS
·
24 Jun

Nektar Shares More Than Double Premarket to $25 After Eczema Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
24 Jun

BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
24 Jun

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Reuters
·
24 Jun

Rezolve-Ad Phase 2B Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
24 Jun

Nektar Therapeutics - Safety Profile Consistent With Previously Reported Results

THOMSON REUTERS
·
24 Jun

Nektar Therapeutics: Data Expected in Q1 2026 From Treatment of Patients With Atopic Dermatitis in Long-Term Maintenance Part of Rezolve-Ad Study

THOMSON REUTERS
·
24 Jun

Nektar Therapeutics -Top-Line Phase 2B Data for Rezpegaldesleukin in Alopecia Areata Expected in Q4 2025

THOMSON REUTERS
·
24 Jun

Nektar Therapeutics - Achieved Statistical Significance on Primary Endpoint at Week 16

THOMSON REUTERS
·
24 Jun

Stocks to Watch: Nektar Therapeutics, Alset

Dow Jones
·
24 Jun

Nektar to announce induction period in REZOLVE-AD study of Rezpegaldesleukin

TIPRANKS
·
24 Jun

Nektar Therapeutics to Unveil Top-Line Data from Phase 2b Study of Rezpegaldesleukin for Atopic Dermatitis on June 24, 2025

Reuters
·
24 Jun

Nektar trading halted, news pending

TIPRANKS
·
07 Jun

BRIEF-Nektar Therapeutics Increases Authorized Shares To 390 Million

Reuters
·
07 Jun